Can we predict who will benefit from cladribine? new study aims to find out
NCT ID NCT05797740
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to help doctors personalize treatment decisions for MS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cladribine tablets (Mavenclad)
What this could lead to
If successful, this study could help doctors identify which multiple sclerosis patients are most likely to benefit from cladribine tablets, leading to more personalized treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AHEPA University Hospital of Thessaloniki
Thessaloniki, Greece
-
AZ Groeninge vzw
Kortrijk, Belgium
-
Aiginiteio' Hospital
Athens, Greece
-
Attikon
Athens, Greece
-
CHU Sart Tilman
Liège, Belgium
-
Centro Hospitalar Lisboa Norte Hospital de Santa Maria
Lisbon, Portugal
-
Centro Hospitalar Universitário Lisboa Central - Hospital dos Capuchos
Lisbon, Portugal
-
Centro Hospitalar de São João E. P. E.
Porto, Portugal
-
Centro Hospitalar e Universitario de Coimbra
Coimbra, Portugal
-
Evagelismos
Athens, Greece
-
FN Hradec Králové
Hradec Králové, Czechia
-
FN u sv. Anny Brno
Brno, Czechia
-
Fakultni nemocnice Ostrava
Ostrava, Czechia
-
General Hospital "Agios Andreas"
Pátrai, Greece
-
General Hospital of Athens G.Gennimatas
Thessaloniki, Greece
-
General Miliary Hospital of Athens "401"
Athens, Greece
-
Interbalkan Hospital of Thessaloniki
Thessaloniki, Greece
-
Medical Academy Neurology Clinic
Poznan, Poland
-
Nemocnice Teplice
Teplice, Czechia
-
NeuropsychiatrieHK
Hradec Králové, Czechia
-
Oddział Kliniczny Neurologii, Szpital Uniwersytecki w Krakowie
Krakow, Poland
-
St Luke's Clinic
Thessaloniki, Greece
-
Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego w Szczecinie
Szczecin, Poland
-
UCL Saint Luc
Brussels, Belgium
-
UZ Antwerpen
Edegem, Belgium
-
University Hospital of Larissa
Larissa, Greece
-
University of Ioannina - Neurology department
Ioannina, Greece
-
University of Patras
Pátrai, Greece
-
University of Thrace, Medical School - Neurology Department, Alexandroupoli
Alexandroupoli, Greece
-
Zuyderland
Sittard-Geleen, Netherlands